Zota Health Care LtdQ1 FY27
Zota Health Care Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,081Market Cap: ₹3.8K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- →Aggressive store expansion planned from Q3 and Q4 FY27, with around 650 store additions targeted for the full year.
- →Mature stores (850+ stores) contribute significantly to profitability, offsetting new store expansion impact.
- →Stores typically reach maturity within 12-18 months, with mature stores generating INR4.13 lakh+ GMV/month.
- →Same-store sales growth (SSG) remains strong, with some cohorts showing 30%+ annualized growth.
- →The company expects to become fully cash positive by end of Q4 FY27 or Q1 FY28.
- →Marketing initiatives and brand-building expected to drive demand and penetration, supporting revenue growth.
- →Significant headroom in market penetration as India has ~18-19 lakh pharmacies, while Davaindia has ~2,800 stores currently.
- →Expect meaningful improvement in overall profitability and higher EBITDA margins than FY26 levels going forward.
Margin guidance
Category 3- →EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- →Despite aggressive store expansion from Q3 and Q4 FY27, EBITDA margins are not expected to fall below last year's level due to increasing mature stores contributing higher profitability.
- →Full-year EBITDA margins should improve meaningfully over FY26 levels, with positivity expected from next quarter onwards.
- →Pre-Ind AS EBITDA positivity (cash profitability) is anticipated by Q4 FY27 or latest Q1 FY28.
- →Mature stores generate increasing revenues and margins; vintage stores (opened 2021-24) show 12-15% store-level EBITDA margins and strong same-store sales growth (approx. 30% annualized).
- →Marketing investments will continue to build brand and drive growth, supporting long-term profitability.
- →Operating leverage and scaling mature stores will drive gradual improvement in profit and earnings per share going forward.
Fundraise plans
- →There is no explicit mention of any current or future fundraising plans through debt or equity in the provided excerpts.
- →Discussions around financials focus on operational cash flow improvements, reduction in cash losses, and expectations of reaching cash breakeven by Q4 FY27 or Q1 FY28.
- →Marketing and store expansion are being carefully managed with budgets aligned to growth needs, but no mention of raising fresh capital.
- →Depreciation and finance costs are covered under operating expenses, but no new debt or equity issuance is indicated.
- →Management emphasizes organic growth and improving profitability rather than raising external funds at this stage.
Order book
The provided transcript from Zota Health Care Limited's earnings call does not explicitly mention details about the company's current or expected order book or pending orders. The discussion focuses primarily on store performance, expansion plans, profitability, marketing expenses, and industry penetration. No specific information about order book size or pending orders is disclosed in the transcript.
Capex plans
Yes- →Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
- →The company acquired Globotask IT Consultancy to strengthen internal IT capabilities, enhance data security, reduce reliance on external IT vendors, and achieve cost benefits long-term.
- →No explicit mention of immediate large-scale capital expenditure or capex plans; however, store expansion continues with planned addition of 600-650 stores in the current financial year, indicating ongoing investment in retail footprint and operations.
- →Emphasis on brand building and marketing investments, including brand ambassadors, suggests continued strategic capital allocation toward marketing rather than heavy physical asset investments.
Track Zota Health Care Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- →Despite aggressive store expansion from Q3 and Q4 FY27, EBITDA margins are not expected to fall below last year's level due to increasing mature stores contributing higher profitability.
- →Full-year EBITDA margins should improve meaningfully over FY26 levels, with positivity expected from next quarter onwards.
- →Pre-Ind AS EBITDA positivity (cash profitability) is anticipated by Q4 FY27 or latest Q1 FY28.
- →Mature stores generate increasing revenues and margins; vintage stores (opened 2021-24) show 12-15% store-level EBITDA margins and strong same-store sales growth (approx. 30% annualized).
- →Marketing investments will continue to build brand and drive growth, supporting long-term profitability.
- →Operating leverage and scaling mature stores will drive gradual improvement in profit and earnings per share going forward.
Order book
The provided transcript from Zota Health Care Limited's earnings call does not explicitly mention details about the company's current or expected order book or pending orders. The discussion focuses primarily on store performance, expansion plans, profitability, marketing expenses, and industry penetration. No specific information about order book size or pending orders is disclosed in the transcript.
How does Zota Health Care Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Zota Health Care Ltd
Rev 2Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Zota Health Care Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zota Health Care Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.